X0508 4 2025-12-22 0001598646 Minerva Neurosciences, Inc. NERV 0002095703 Kaul Inderjit C/O MINERVA NEUROSCIENCES, INC. 1500 DISTRICT AVENUE BURLINGTON MA 01803 true false false false 0 Stock Option (right to buy) 3.98 2025-12-22 4 A 0 364504 0 A 2035-12-21 Common Stock 364504 364504 D 25% of the option shall vest on November 14, 2026; an additional 45% of the option shall vest on the tenth day following the date of the Issuer's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the option shall vest on the tenth day following the date of the Issuer's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date. /s/ Geoff Race, Attorney-in-Fact 2025-12-23